DHARMESH S. PATEL
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
- Where
- SOUTHAVEN, MS
- NPI
- 1689651036
- Received
- $1,551,099 in 2,273 records, 2019 to 2025 ($1,546,955 general, $4,144 research)
- As principal investigator
- $382,748 of research payments to others in 46 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 426 | $334,198 |
| 2024 | General payment | 402 | $259,097 |
| 2024 | Research payment | 1 | $4,144 |
| 2023 | General payment | 295 | $158,223 |
| 2022 | General payment | 325 | $185,869 |
| 2021 | General payment | 247 | $180,866 |
| 2020 | General payment | 180 | $174,348 |
| 2019 | General payment | 397 | $254,352 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 506 | $1,165,754 |
| Consulting Fee | 62 | $177,290 |
| Travel and Lodging | 417 | $152,202 |
| Food and Beverage | 1,271 | $45,508 |
| Compensation for serving as faculty or as a speaker for a medical education program | 5 | $5,875 |
| Research payment | 1 | $4,144 |
| Education | 10 | $274 |
| Entertainment | 1 | $50 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-24 | Amgen Inc. | $663 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $2,087 | Consulting Fee | Cash or cash equivalent | EVKEEZA Biological, CARDIOVASCULAR AND METABOLIC | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $1,252 | Consulting Fee | Cash or cash equivalent | EVKEEZA Biological, CARDIOVASCULAR AND METABOLIC | 2025 | |
| 2025-12-19 | Medtronic, Inc. | $400 | Consulting Fee | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | 2025 | |
| 2025-12-18 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-17 | Amgen Inc. | $75 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-16 | Alnylam Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-12-16 | Philips North America LLC | $19 | Food and Beverage | Cash or cash equivalent | MCOT Device, Medical Device | 2025 | |
| 2025-12-15 | Medtronic, Inc. | $1,400 | Consulting Fee | Cash or cash equivalent | SYMPLICITY G3 Device, Renal Denervation System | 2025 | |
| 2025-12-12 | Amgen Inc. | $107 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-12 | Amgen Inc. | $66 | Food and Beverage | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-12 | Amgen Inc. | $48 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-12 | Amgen Inc. | $21 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-11 | Amgen Inc. | $116 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-09 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-09 | Amgen Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-09 | Amgen Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-09 | Bayer Healthcare Pharmaceuticals Inc. | $8 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-12-08 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-12-04 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-04 | Amgen Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-04 | Amgen Inc. | $72 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-02 | Bayer Healthcare Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-12-01 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-12-01 | Amgen Inc. | $745 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-26 | Amgen Inc. | $390 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-26 | Amgen Inc. | $321 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-26 | Amgen Inc. | $37 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-26 | Amgen Inc. | $28 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-26 | Amgen Inc. | $18 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-26 | Medtronic, Inc. | $13 | Food and Beverage | In-kind items and services | AURORA EV-ICD MRI SURESCAN Device, Implant Cardio Defib - ICDs | 2025 | |
| 2025-11-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-25 | Regeneron Pharmaceuticals, Inc. | $143 | Food and Beverage | In-kind items and services | EVKEEZA Biological, CARDIOVASCULAR AND METABOLIC | 2025 | |
| 2025-11-25 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $31 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-11-24 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-21 | Bayer Healthcare Pharmaceuticals Inc. | $1,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-20 | Novo Nordisk Inc | $8,046 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-20 | Novo Nordisk Inc | $1,105 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-20 | Amgen Inc. | $691 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-20 | Amgen Inc. | $551 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-20 | Novo Nordisk Inc | $93 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | Medtronic, Inc. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | 2025 | |
| 2025-11-19 | Amgen Inc. | $110 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-19 | Amgen Inc. | $6 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-18 | Amgen Inc. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-18 | Medtronic, Inc. | $1,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-18 | Amgen Inc. | $962 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-18 | Amgen Inc. | $623 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-18 | Amgen Inc. | $611 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-18 | Amgen Inc. | $104 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-17 | Amgen Inc. | $125 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-14 | Bayer Healthcare Pharmaceuticals Inc. | $5,528 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-12 | Ionis Pharmaceuticals, Inc. | $8,525 | Consulting Fee | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-11-12 | Ionis Pharmaceuticals, Inc. | $67 | Travel and Lodging | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-11-12 | Ionis Pharmaceuticals, Inc. | $48 | Travel and Lodging | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-11-12 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-12 | Ionis Pharmaceuticals, Inc. | $21 | Travel and Lodging | Cash or cash equivalent | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-11-12 | Ionis Pharmaceuticals, Inc. | $18 | Travel and Lodging | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-11-10 | Abbott Laboratories | $101 | Food and Beverage | In-kind items and services | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart | 2025 | |
| 2025-11-09 | Esperion Therapeutics, Inc. | $103 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-11-08 | Ionis Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-07 | Bayer Healthcare Pharmaceuticals Inc. | $5,528 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-07 | Medtronic, Inc. | $489 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-07 | Medtronic, Inc. | $176 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-06 | Amgen Inc. | $623 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-11-06 | Boston Scientific Corporation | $30 | Food and Beverage | In-kind items and services | WATCHMAN FLX Device, WATCHMAN FLX_IC | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $985 | Travel and Lodging | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-05 | Cleerly, Inc. | $155 | Food and Beverage | Cash or cash equivalent | Cleerly Ischemia Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $124 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $6,868 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $697 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Novo Nordisk Inc | $125 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-04 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | CAPVAXIVE Biological, VACCINE | 2025 | |
| 2025-11-01 | Bayer Healthcare Pharmaceuticals Inc. | $33 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,197 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-30 | Bayer Healthcare Pharmaceuticals Inc. | $64 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-30 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-10-29 | Novo Nordisk Inc | $25 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-28 | Philips North America LLC | $18 | Food and Beverage | Cash or cash equivalent | Ambulatory Monitoring & Diagnostics Undivided Device, Medical Device | 2025 | |
| 2025-10-28 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-24 | Bayer Healthcare Pharmaceuticals Inc. | $4,791 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-24 | Lilly USA, LLC | $1,560 | Consulting Fee | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-22 | Bayer Healthcare Pharmaceuticals Inc. | $877 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-22 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-21 | Bayer Healthcare Pharmaceuticals Inc. | $125 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-21 | Amgen Inc. | $87 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-17 | Alnylam Pharmaceuticals Inc. | $10 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-10-16 | AstraZeneca Pharmaceuticals LP | $108 | Food and Beverage | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-10-16 | AstraZeneca Pharmaceuticals LP | $17 | Travel and Lodging | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-10-15 | Bayer Healthcare Pharmaceuticals Inc. | $5,528 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-15 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-15 | Esperion Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-10-10 | Bayer Healthcare Pharmaceuticals Inc. | $5,528 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-09 | Bayer Healthcare Pharmaceuticals Inc. | $1,606 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-07 | Bayer Healthcare Pharmaceuticals Inc. | $103 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-06 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,300 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-04 | Ionis Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | TRYNGOLZA Drug, CARDIOLOGY | 2025 | |
| 2025-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-04 | Ionis Pharmaceuticals, Inc. | $5 | Food and Beverage | In-kind items and services | TRYNGOLZA Drug, CARDIOLOGY | 2025 | |
| 2025-10-03 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-10-03 | Bayer Healthcare Pharmaceuticals Inc. | $6 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-03 | Bayer Healthcare Pharmaceuticals Inc. | $2 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-02 | Bayer Healthcare Pharmaceuticals Inc. | $4,054 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-01 | Bayer Healthcare Pharmaceuticals Inc. | $116 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-30 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-29 | Bayer Healthcare Pharmaceuticals Inc. | $1,300 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-29 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-27 | Ionis Pharmaceuticals, Inc. | $49 | Travel and Lodging | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-09-27 | Ionis Pharmaceuticals, Inc. | $39 | Food and Beverage | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-09-27 | Ionis Pharmaceuticals, Inc. | $37 | Food and Beverage | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-09-27 | Ionis Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-09-26 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-26 | Ionis Pharmaceuticals, Inc. | $858 | Travel and Lodging | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-09-26 | Ionis Pharmaceuticals, Inc. | $305 | Travel and Lodging | In-kind items and services | OLEZARSEN Drug, CARDIOLOGY | 2025 | |
| 2025-09-25 | Alnylam Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-09-23 | Novo Nordisk Inc | $3,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-09-23 | Bayer Healthcare Pharmaceuticals Inc. | $547 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-22 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-18 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-18 | Amgen Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-18 | Novo Nordisk Inc | $27 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-09-17 | Bayer Healthcare Pharmaceuticals Inc. | $150 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-17 | Amgen Inc. | $61 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-15 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-12 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-12 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-11 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-11 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $19 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-09-10 | Esperion Therapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-09-09 | Amgen Inc. | $10 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-08 | Philips North America LLC | $20 | Food and Beverage | Cash or cash equivalent | Ambulatory Monitoring & Diagnostics Undivided Device, Medical Device | 2025 | |
| 2025-09-05 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-04 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-04 | Amgen Inc. | $75 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-04 | Amgen Inc. | $10 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-09-04 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $7 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-09-04 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $5 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-09-03 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-09-03 | Medtronic, Inc. | $140 | Food and Beverage | In-kind items and services | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | 2025 | |
| 2025-09-02 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-29 | Bayer Healthcare Pharmaceuticals Inc. | $4,054 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-29 | Bayer Healthcare Pharmaceuticals Inc. | $128 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-29 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-28 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-27 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-27 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-08-27 | Bayer Healthcare Pharmaceuticals Inc. | $11 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-27 | Amgen Inc. | $9 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-26 | Novo Nordisk Inc | $7,653 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-08-26 | Novo Nordisk Inc | $595 | Travel and Lodging | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-08-26 | Novo Nordisk Inc | $95 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-08-25 | Philips North America LLC | $18 | Food and Beverage | Cash or cash equivalent | Ambulatory Monitoring & Diagnostics Undivided Device, Medical Device | 2025 | |
| 2025-08-23 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-08-22 | Bayer Healthcare Pharmaceuticals Inc. | $7,002 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-21 | Bayer Healthcare Pharmaceuticals Inc. | $117 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-21 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-21 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-19 | Alnylam Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-19 | Alnylam Pharmaceuticals Inc. | $4 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $275 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $161 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $115 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-17 | Bayer Healthcare Pharmaceuticals Inc. | $48 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-15 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-15 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $24 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-08-14 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-14 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-08-12 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage (2 payments) | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-08-11 | Philips North America LLC | $16 | Food and Beverage | Cash or cash equivalent | Ambulatory Monitoring & Diagnostics Undivided Device, Medical Device | 2025 | |
| 2025-08-08 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-08 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-08-07 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-07 | Bayer Healthcare Pharmaceuticals Inc. | $120 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-06 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-08-06 | Amgen Inc. | $805 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-05 | Amgen Inc. | $88 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-01 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-01 | Amgen Inc. | $1,028 | Travel and Lodging | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-08-01 | Amgen Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-31 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-07-29 | Bayer Healthcare Pharmaceuticals Inc. | $762 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-29 | Amgen Inc. | $121 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-29 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | EVKEEZA Biological, CARDIOVASCULAR AND METABOLIC | 2025 | |
| 2025-07-25 | Amgen Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-25 | Amgen Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-25 | Abbott Laboratories | $136 | Food and Beverage | In-kind items and services | AVEIR Device, Structural Heart | 2025 | |
| 2025-07-24 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-23 | Lilly USA, LLC | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-07-22 | Amgen Inc. | $118 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-19 | Philips North America LLC | $75 | Food and Beverage | Cash or cash equivalent | Ambulatory Monitoring & Diagnostics Undivided Device, Medical Device | 2025 | |
| 2025-07-18 | Esperion Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-07-17 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-16 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-07-15 | Bayer Healthcare Pharmaceuticals Inc. | $379 | Travel and Lodging | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-07-15 | Amgen Inc. | $10 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 |
The latest 200 records of 2,273.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-09-23 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION INC | $10,815 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici | 2025 |
| 2025-09-08 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION | $530 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Partici | 2025 |
| 2025-06-27 | Chiesi USA, Inc. | STERN CARDIOVASCULAR FOUNDATION INC | $190 | LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | 2025 |
| 2025-01-28 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $20,932 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-01-17 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION | $4,376 | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 |
| 2025-01-17 | Chiesi USA, Inc. | STERN CARDIOVASCULAR FOUNDATION INC | $190 | LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $13,100 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2025 |
| 2025-01-07 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $8,205 | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2025 |
| 2024-07-02 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION | $2,287 | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 |
| 2024-06-30 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION | $24 | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-06-27 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $20,930 | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pe | 2024 |
| 2024-06-26 | Chiesi USA, Inc. | STERN CARDIOVASCULAR FOUNDATION INC | $93 | LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | 2024 |
| 2024-03-13 | Chiesi USA, Inc. | STERN CARDIOVASCULAR FOUNDATION INC | $634 | LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | 2024 |
| 2024-01-18 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $24,449 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2024 |
| 2024-01-15 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $1,060 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2024 |
| 2023-07-26 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $364 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2023 |
| 2023-03-22 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $91 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2023 |
| 2023-03-13 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $190 | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and T | 2023 |
| 2023-02-01 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $3,450 | A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and T | 2023 |
| 2023-01-26 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $72,119 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2023 |
| 2023-01-15 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $1,657 | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T | 2023 |
| 2022-11-17 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION INC CLCZ696BUS13 | $8,345 | A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, 20-WEEK DOSE-FINDING STUDY TO EVALUATE EFFICACY, SAFETY, AND T | 2022 |
| 2022-09-21 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $180 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2022 |
| 2022-06-15 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $89 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2022 |
| 2022-06-15 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $50 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2022 |
| 2022-02-04 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION | $8,312 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR | 2022 |
| 2022-01-19 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $178 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2022 |
| 2022-01-15 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION INC CLCZ696BUS13 | $99,328 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2022 |
| 2021-07-28 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $50 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2021 |
| 2021-07-28 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $263 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2021 |
| 2021-05-25 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $5,062 | MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEV | 2021 |
| 2021-05-05 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $50 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2021 |
| 2021-05-05 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $522 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2021 |
| 2021-01-15 | Novartis Pharmaceuticals Corporation | THE STERN CARDIOVASCULAR FOUNDATION | $49,254 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2021 |
| 2020-10-26 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION INC | $192 | A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH T | 2020 |
| 2020-10-13 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION | $19,532 | MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEV | 2020 |
| 2020-09-30 | Amryt Pharma Holdings Ltd | Stern Cardiovascular Foundation, Inc. | $255 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-04-01 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $576 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-04-01 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $100 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-01-29 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $25 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-01-29 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $882 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-01-29 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $25 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-01-29 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $25 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-01-29 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $50 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2020-01-29 | Amryt Pharma Holdings Ltd | STERN CARDIOVASCULAR FOUNDATION INC | $50 | LOWER: Lomitapide Observational Worldwide Evaluation Registry | 2020 |
| 2019-10-09 | Novartis Pharmaceuticals Corporation | STERN CARDIOVASCULAR FOUNDATION INC | $3,660 | A 52 WEEK OPEN LABEL EVALUATION OF THE EFFECTS OF SACUBITRIL VALSARTAN LCZ696 THERAPY ON BIOMARKERS MYOCARDIAL REMODELIN | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Southaven, MS, county DeSoto County, MS, state Mississippi; placed by its city name.
| Measure | Place (city or town) Southaven, MS | County DeSoto County, MS | State Mississippi |
|---|---|---|---|
| Population B01003 | 56,226 | 191,301 | 2,946,779 |
| Population, 2020 census P1 | 54,648 | 185,314 | 2,961,279 |
| Median age B01002 | 36.2 | 37.3 | 38.6 |
| Under 18 B01001 | 25.5% | 25.0% | 23.3% |
| 65 and over B01001 | 13.2% | 13.5% | 17.2% |
| Households B11001 | 21,251 | 70,986 | 1,145,431 |
| Foreign born B05002 | 3.4% | 4.0% | 2.4% |
| Median household income B19013 | $78,483 | $85,297 | $56,447 |
| Median family income B19113 | $93,418 | $99,516 | $73,163 |
| Per capita income B19301 | $35,303 | $38,113 | $31,549 |
| Poverty rate B17001 | 12.6% | 9.7% | 18.9% |
| Unemployment rate B23025 | 3.3% | 3.2% | 5.8% |
| Civilian labor force B23025 | 29,296 | 100,011 | 1,332,121 |
| Mean commute (minutes) B08013 | 24.0 | 26.2 | 25.6 |
| Bachelor's degree or higher B15003 | 28.8% | 29.0% | 25.1% |
| Housing units B25001 | 23,046 | 75,437 | 1,341,114 |
| Owner-occupied B25003 | 72.5% | 77.9% | 70.0% |
| Renters B25003 | 27.5% | 22.1% | 30.0% |
| Median home value B25077 | $236,300 | $269,600 | $169,800 |
| Median gross rent B25064 | $1,445 | $1,451 | $954 |
| White, not Hispanic B03002 | 50.7% | 56.4% | 55.2% |
| Black B03002 | 39.3% | 32.6% | 36.3% |
| Hispanic or Latino B03002 | 5.3% | 5.8% | 3.7% |
| Asian B03002 | 1.2% | 1.3% | 1.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.4% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Southaven, MS.
Comments